{
  "meta": {
    "title": "Heparin_Lmwh_Direct_Thrombin_Inhibitors_Thromolytics_Warfarin_Antiplatelets",
    "url": "https://brainandscalpel.vercel.app/heparin-lmwh-direct-thrombin-inhibitors-thromolytics-warfarin-antiplatelets-177ce420.html",
    "scrapedAt": "2025-11-30T08:50:54.070Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Complete absence of bleeding complications</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Good oral bioavailability</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Lower incidence of drug-induced thrombocytopenia</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Pronounced anti-platelet activity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 67-year-old woman presented to the medicine OPD with complaints of progressive swelling and soreness of the left calf. After physical examination and laboratory examination, a diagnosis of deep venous thrombosis was made, and a treatment with enoxaparin was started. Which of the following is the main advantage of this drug over the standard unfractionated heparin?</span></p>",
      "unique_key": "DT1292834",
      "question_audio": null,
      "question_video": null,
      "map_id": 1292834,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>High-molecular-weight heparin (HMWH) causes <strong>transient</strong> thrombocytopenia <strong>in up to 15% of patients</strong></u></em><em> and <strong>severe</strong> thrombocytopenia (which is antibody-mediated) <strong>in up to 5% of patients.</strong></em></p>\r\n<p><strong><em><u>Enoxaparin is a low-molecular-weight heparin (LMWH). </u></em></strong><em><u>LMWH-induced thrombocytopenia is seen in less than 1% of patients.</u></em></p>\r\n<p><em>A <u>LMWHs cause a <strong>lower incidence of bleeding complications</strong></u><strong>, </strong>which could be related to the fact that these agents <strong><u>preferentially inhibit factor Xa more potently than they inhibit thrombin (thrombin inhibition requires a larger heparin molecule).</u></strong></em></p>\r\n<p><strong><em><u>Advantages of LMWH over Heparin</u></em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412234a3a0707-c58c-4d5d-aa7a-567b94a.jpg\">\r\n<p>Option A: <em>bleeding complications are less, do occur even with LMWH.</em></p>\r\n<p>Option B: LMWH has Greater Bioavailability but when given Subcutaneously.</p>\r\n<p>Option C: LMWH has Lesser anti platelet activity and Bleeding Complications.</p>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li><strong><em>LMWH has Lower incidence of Drug induced Thrombocytopenia &amp; Bleeding Risk compared to Unfractionated HMWH. </em></strong></li>\r\n</ul>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Streptokinase</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 30-year-old woman presented to her family physician complaining of black, tarry stools. The woman had a history of prosthetic valve replacement before a few months earlier for severe aortic stenosis secondary to rheumatic disease and had been receiving daily oral anticoagulant therapy since then. Physical examination revealed subconjunctival hemorrhage and bruises on her arms and legs. Which of the following drugs most likely caused the patient's signs and symptoms?</span></p>",
      "unique_key": "DT1293209",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293209,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em>The primary approach to prevent valvular thrombosis and systemic thromboembolism associated with <strong><u>mechanical prosthetic valve replacement is long-term anticoagulation with warfarin</u>. </strong></em></p>\r\n<p><em>Most likely, <u>the dose of warfarin was too high, so bleeding occurred, as pointed out by the signs and symptoms of the patient.</u></em></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412238e660f30-d0bd-4cb8-939e.jpg\">\r\n<p><strong>Option A</strong>: Fibrinolytic drugs such as streptokinase are <strong>not indicated for long-term prevention of thrombosis.</strong></p>\r\n<p><strong>Option B</strong>: Aspirin is sometimes used together with warfarin in treating patients with prosthetic valves, mainly when evidence of thromboembolism exists despite adequate anticoagulation. <strong>However, it is not effective for prevention when given alone.</strong></p>\r\n<p><strong>Option C</strong>: Heparin and bivalirudin <strong>must be given parenterally</strong> and therefore are not suited for long-term anticoagulation.</p>\r\n<p><strong><u>Key Takeaway :</u></strong></p>\r\n<ul>\r\n<li><strong><em><u>Bleeding is the most common</u></em></strong><em><u> adverse effect of all anticoagulants</u></em>. If a patient develops bleeding due to overdose of warfarin, <strong>four factor concentrate or fresh frozen plasma</strong> (to supply clotting factors) is the treatment of choice but <strong><em>specific antidote is vitamin K</em></strong><strong><em>1</em></strong> (but the action will be delayed).</li>\r\n</ul>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Fondaparinux</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Dabigatran</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old male patient had a history of ongoing cancer chemotherapy presented to medicine OPD with sudden onset breathlessness, chest pain, palpitations and cough. On further investigations, CT scan of chest confirmed the diagnosis of pulmonary embolism. Which of the following anticoagulant agent is the drug of choice for the management of cancer-associated thromboembolism? </span></p>",
      "unique_key": "DT1293211",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293211,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>Heparin, LMWH, or fondaparinux</u></em><em> can be used to initiate treatment of deep vein thrombosis and pulmonary embolism. They also can be used for the <strong><u>initial management of patients with unstable angina or acute myocardial infarction</u></strong></em><strong><em>.</em></strong></p>\r\n<ul>\r\n<li><strong><em><u>For most of these indications, LMWH or fondaparinux has replaced continuous heparin infusions because of the following advantages:</u></em></strong>\r\n<ul>\r\n<li><strong><em>Pharmacokinetic advantages:</em></strong></li>\r\n<li><em>Subcutaneous administration once or twice daily in fixed or weight-adjusted doses </em></li>\r\n<li><strong><em>No need for coagulation monitoring.</em></strong></li>\r\n</ul>\r\n</li>\r\n<li><em>Thus, LMWH or <u>fondaparinux can be used for out-of-hospital management of patients with deep vein thrombosis or pulmonary embolism.</u></em></li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412237c19a6b8-784a-48c5-a038.jpg\">\r\n<p><strong>Option B: </strong><em>The effect of oral anticoagulants <strong>is always delayed </strong>(develops gradually over 1-3 days) and these are thus used for <strong>maintenance</strong> of anticoagulation rather than initiation of treatment. </em></p>\r\n<p><strong>Option C &amp; D: </strong><em>Heparin and dabigatran can be used in pulmonary embolism but <strong>because of the pharmacokinetic advantages and safety profile,</strong> fondaparinux is a more preferred agent.</em></p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em>Fondaparinux can be used for <strong>out-of-hospital management of patients with deep vein thrombosis or pulmonary embolism </strong>because of the safety profile of it as compared to other agents.</em></li>\r\n</ul>",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Red blood cell count (RBC)</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Platelet count</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Plasma K+ level</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Bleeding time</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 71-year-old woman who underwent hip replacement was discharged from the hospital with an appropriate post-discharge therapy that included daily subcutaneous injection of regular heparin. Which of the following laboratory examinations should be performed frequently during the heparin treatment?</span></p>",
      "unique_key": "DT1293213",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293213,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>High-molecular-weight heparin (HMWH) causes <strong>transient</strong> thrombocytopenia in up to <strong>15</strong>% of patients</u></em><em> and <strong>severe</strong> thrombocytopenia (which is antibody-mediated) in up to <strong>5</strong>% of patients. </em></p>\r\n<p><em>Because <u>heparin-induced thrombocytopenia (HIT) is a serious adverse effect of heparin</u>, a <strong>platelet count should be performed weekly during heparin treatment. </strong></em></p>\r\n<p><strong><em>Any thrombocytopenia appearing during treatment should be considered suspicious for HIT.</em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241223d48c9e7a-c5ed-4a1b-a67a.jpg\">\r\n<p>Option A: Heparin doesn't alter RBC Count.</p>\r\n<p>Option C: Heparin causes Hyperkalemia but It doesn't Require Periodic Checkup.</p>\r\n<p>Option D: Heparin action is monitored with aPTT. ( Vs BT Not Required)</p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><strong><em>Heparin-induced thrombocytopenia (HIT) is a serious </em></strong><em>adverse effect of heparin, <strong>a platelet count should be performed weekly </strong>during heparin treatment.</em></li>\r\n</ul>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Dacetuzumab</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Idarucizumab </span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Pembrolizumab</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Natalizumab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old female presented to medicine OPD seeking treatment for deep vein thrombosis. Later, she was prescribed dabigatran by her physician. As the patient was also having mild renal impairment, there were multiple hemorrhagic episodes due to dabigatran toxicity. Which of the following monoclonal antibody is approved for the reversal of serious bleeding due to dabigatran toxicity? </span></p>",
      "unique_key": "DT1293216",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293216,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>Bleeding is the major side effect of dabigatran. </u></em></p>\r\n<p><em>In elderly patients with atrial fibrillation, <u>the risk of major bleeding with dabigatran is like that with warfarin, about 3.0%.</u> However, the risk of <strong>intracranial bleeding is reduced by 70%</strong> with dabigatran compared with warfarin. </em></p>\r\n<p><em><u>Additional risk factors for bleeding with dabigatran <strong>include renal impairment and concurrent use of antiplatelet agents or nonsteroidal anti-inflammatory drugs</strong></u></em><strong><em>. </em></strong></p>\r\n<p><strong><em><u>Idarucizumab</u></em></strong></p>\r\n<ul>\r\n<li><em><u>Idarucizumab, A specific reversal agent for dabigatran, is a humanized mouse monoclonal antibody fragment directed against dabigatran.</u></em></li>\r\n<li><em>The <strong>antibody binds dabigatran with an affinity 350-fold higher than that of dabigatran for thrombin</strong>, and the <u>essentially irreversible idarucizumab-dabigatran complex is cleared by the kidneys.</u></em></li>\r\n<li><em>It <u>rapidly reverses the anticoagulant effects of dabigatran, and patients </u></em><em><u>have then safely undergone major surgery.</u></em></li>\r\n</ul>\r\n<p><strong><u>Reversal Agents for Direct Oral Anticoagulants</u></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412233001c94d-fa99-45ce-b3f2.jpg\">\r\n<p><strong>Option A: TCR signaling on CD4+ cells after engagement with an MHC class II-peptide complex </strong>is enhanced by activating coreceptors CD 40 &amp; CD 150 which is activated by Dacetuzumab.</p>\r\n<p><strong>Option C: </strong>Pembrolizumab is monoclonal antibodies <strong>against PD-1 receptors on T-cells.</strong></p>\r\n<p><strong>Option D: </strong>Natalizumab is highly effective in <strong>multiple sclerosis.</strong></p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em>Idarucizumab, <strong>A specific reversal agent for dabigatran,</strong> is a humanized mouse monoclonal antibody fragment directed against dabigatran.</em></li>\r\n</ul>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Alteplase</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old man developed sudden dyspnea and chest pain 2 days post surgery. Physical examination revealed an anxious man in severe respiratory distress with the following vital signs: temperature 99.5&deg;F, pulse 120 bpm, blood pressure 90/50 mm Hg, respirations 28 breaths/min. A computed tomography scan showed complete obstruction of a branch of the left pulmonary artery. Which of the following drugs should be included in the acute parenteral treatment of this patient?</span></p>",
      "unique_key": "DT1293230",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293230,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em>The <u>sudden dyspnea, hypotension, and pleuritic chest pain, particularly in a high-risk setting, would suggest the diagnosis of massive pulmonary embolism, which is confirmed by the computed tomography</u> scan. </em></p>\r\n<p><strong><em>Heparin is a drug of choice to prevent further thrombus formation and embolization.</em></strong></p>\r\n<p><strong>Option B</strong>: Aspirin has been <strong><u>tried to prevent</u></strong> thromboembolism, but results are <strong>inconclusive</strong>. Moreover, they are not given parenterally.</p>\r\n<p><strong>Option C</strong>: The systemic hypotension and extreme hypoxemia warrant consideration of thrombolytic therapy. However, <strong><em><u>recent surgery (as in this case) is a major contraindication for fibrinolytic drugs</u></em>.</strong></p>\r\n<p><strong>Option D</strong>: Warfarin is not used for the acute treatment of pulmonary embolism because of its <strong>slow onset of action.</strong></p>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li><strong><em>When Thrombolytics are Contraindicated</em></strong><em> in Massive Pulmonary Embolism, heparin is a drug of choice <strong>to prevent further thrombus formation and embolization. </strong></em></li>\r\n</ul>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase the dose of warfarin </span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Replace warfarin with acenocoumarol</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Switch ethambutol for rifampicin </span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Use LMWH </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old diabetic female patient with a history of active Tuberculosis was on Isoniazid and Rifampicin for the same. Later, she was brought to the surgical department with signs of Deep Venous Thrombosis (DVT). She was started on warfarin, but Prothrombin time (PT) is not raised. Which of the following is the most accurate step to be taken?</span></p>",
      "unique_key": "DT1293231",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293231,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>The <strong><em>anticoagulant effect of warfarin is assessed by the measurement of prothrombin time (PT).</em></strong> Failure of <u>elevation of PT indicates the decreased effect of warfarin.</u></p>\r\n<p><strong><em>The effect of oral anticoagulants is always delayed (develops gradually over 1-3 days) and these are thus used for maintenance of anticoagulation rather than initiation of treatment.</em></strong></p>\r\n<p>Option A : <strong><em>Effect of warfarin starts in 4-5 days. Therefore, if we increase the dose of warfarin, it will take 5 days to prevent DVT. </em></strong>For <strong><u>immediate action, heparin, or LMWH has to be started</u></strong>.</p>\r\n<p><strong>Option B:</strong> Acenocoumarin is also an oral anticoagulant <strong>with MOA Like Warfarin</strong> with delayed effects. Its metabolism is also subjected to <strong>induction by rifampicin. </strong></p>\r\n<p><strong>Option C:</strong> <em><u>Rifampicin is an <strong>enzyme inducer </strong>and can decrease the effect of warfarin.</u></em> However, Rifampicin is the most effective drug for tuberculosis and <strong>should not be replaced.</strong></p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em>The effect of oral anticoagulants is <strong>always delayed</strong> (develops gradually over 1-3 days) and these are thus used for <strong>maintenance of anticoagulation rather than initiation of treatment.</strong></em></li>\r\n</ul>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin increases activity of antithrombin</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Serine proteases of the clotting cascade are deactivated</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin catalyzes clotting in vitro</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin aids sequestration of lipoproteins</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old woman undergoes an open cholecystectomy. She is admitted for postoperative observation and started on subcutaneous heparin treatment to prevent formation of deep venous thrombosis, a major risk factor for pulmonary embolism. Which of the following is the most accurate regarding the mechanism of action of heparin?</span></p>",
      "unique_key": "DT1293233",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293233,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em>Heparin increases the activity of </em><em><u>antithrombin by 1000-fold.</u></em></p>\r\n<p><em>Anti-thrombin, in turn, <strong>activates</strong> serine proteases of the clotting cascade. Heparin has a direct anticoagulant activity and can <strong>inhibit</strong> clotting in vitro. </em></p>\r\n<p><strong><em><u>Heparin enhances the action of AT-III in two ways</u></em></strong></p>\r\n<p>(A) The <em><u>long heparin molecule provides a scaffolding for the clotting factors (mainly Xa and IIa) on one hand and AT-III on the other, so that they interact with each other.</u></em></p>\r\n<p>(B) <em><u>Heparin induces conformational change in AT-III to expose its interactive sites. </u></em></p>\r\n<p>A <em><u>specific pentasaccharide sequence, which is present in only some of the heparin molecules, binds to AT III with high affinity to induce the conformational change</u></em> needed for rapid interaction with clotting factors.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241223a385abf1-795e-4b0e-aca4-612c1b6.jpg\">\r\n<p>Option B: Serine proteases of the clotting cascade are <strong>activated.</strong></p>\r\n<p>Option C: Heparin <strong>Inhibits</strong> clotting in vitro.</p>\r\n<p>Option D: Heparin Provides Scaffolding To Clotting factors.</p>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li><em>Heparin <strong>increases the activity of antithrombin by 1000-fold. Anti-thrombin, in turn, activates serine proteases of the clotting cascade. Heparin has a direct anticoagulant activity and can inhibit clotting in vitro.</strong></em></li>\r\n</ul>",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Unfractionated heparin</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Enoxaparin</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Dalteparin</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Fondaparinux</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Anticoagulant activity of which amongst the following agents is not affected by use of protamine sulfate?</span></p>",
      "unique_key": "DT1293235",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293235,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em><u>Effects of fondaparinux cannot be reversed by protamine sulfate </u></em></strong></p>\r\n<ul>\r\n<li><strong>Protamine sulfate </strong>It is a strongly <strong><u>basic, low molecular weight protein</u></strong> obtained from the sperm of certain fish. Given i.v. it neutralises heparin mg for mg, i.e. <strong><em>1 mg is needed for every 100 U of heparin.</em></strong></li>\r\n<li><strong><em>Protamine is more commonly used when heparin action needs to be terminated rapidly</em></strong>, e.g. after cardiac or vascular surgery.</li>\r\n<li><em>Protamine sulfate binds and neutralizes unfractionated </em><em>heparin, resulting in the complete reversal of both anti-factor Ila and Xa activity.</em></li>\r\n<li>Protamine sulfate <strong><u>reverses the anti-factor lla activity of LMWH completely</u></strong> and anti-factor Xa partially because the shorter chains cannot be neutralized.</li>\r\n<li>Protamine <strong><em><u>does not</u> neutralize fondaparinux</em></strong>, and it only <strong><em><u>partially</u> reverses the anticoagulant effect of LMW heparins.</em></strong></li>\r\n</ul>\r\n<p><strong>Option A : </strong><em>Protamine sulfate binds and neutralizes unfractionated heparin <strong>completely. </strong></em></p>\r\n<p><strong>Option B : </strong><em>Protamine sulfate binds and neutralizes LMWH <strong>Partially.</strong></em></p>\r\n<p><strong>Option C</strong>: <em>Protamine sulfate binds and neutralizes LMWH <strong>Partially.</strong></em></p>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li>Protamine <strong><em><u>does not</u> neutralize</em></strong><em> fondaparinux</em>, and it <strong>only <em><u>partially</u> reverses</em></strong><em> the anticoagulant effect of LMW heparins.</em></li>\r\n</ul>",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Prothrombin synthesis</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Thromboxane A2 activity</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombin activity</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Antithrombin III activity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old man recently diagnosed with atrial fibrillation started a treatment that included dabigatran. The inhibition of which of the following molecular actions most likely mediated the therapeutic effect of the drug in this patient?</span></p>",
      "unique_key": "DT1293237",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293237,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>Dabigatran is a new oral anticoagulant that acts by binding reversibly to thrombin, thus blocking thrombin activity</u></em>.</p>\r\n<p><strong><em>Advantages of direct thrombin inhibitor over Warfarin</em></strong></p>\r\n<ul>\r\n<li><em><u>Rapid onset of action, </u></em></li>\r\n<li><em><u>Does not interact with p-450-interacting drugs</u></em></li>\r\n<li><em><u>Gives a predictable anticoagulant response</u></em></li>\r\n<li><em><u>Routine anticoagulant monitoring not required</u></em>.</li>\r\n</ul>\r\n<p><strong><em><u>ORAL ANTICOAGULANTS</u></em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241223a88a8367-1f7a-4854-b37d.jpg\">\r\n<p>Option A: Prothrombin Synthesis inhibited by Coumarins.</p>\r\n<p>Option B: TAX-2 Activity inhibited by Aspirin.</p>\r\n<p>Option D: AT-3 Activity is increased by Heparin.</p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em>Dabigatran is a new oral anticoagulant that acts by <strong>binding reversibly to thrombin, thus blocking thrombin activity</strong></em><strong>.</strong></li>\r\n</ul>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Reteplase</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Eptifibatide</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Lovastatin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 53-year-old obese woman is brought into the emergency room within an hour after complaining of constant abdominal pain, nausea, and shortness of breath. An electrocardiogram (ECG) and cardiac enzyme tests indicate a moderate myocardial infarction (MI) due to occlusion of the left descending coronary artery. Which of the following would be the best course of treatment for this patient?</span></p>",
      "unique_key": "DT1293238",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293238,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>Thrombolytics such as the recombinant tissue plasminogen activator(tPA) reteplase reduce morbidity and mortality</u></em><em> if used shortly after an acute myocardial infarction (AMI). </em></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412232936e067-422f-46a7-b296.jpg\">\r\n<p>Option B: <em><u>Heparin might be used after resolution of the Acute MI. </u></em></p>\r\n<p>However it's not a suitable choice for acute myocardial infarction on an immediate basis.</p>\r\n<p>Option C: Eptifibatide is a glycoprotein IIb/IIIa class platelet inhibitor drug that reduces ischemic cardiac events in specific patient populations. However STEMI Requires Thrombolytics therapy.</p>\r\n<p>Option D: <em>If the patient is above recommended levels of low-density lipoprotein (LDL) cholesterol, she should be treated with a cholesterol-lowering drug such as lovastatin. However, it's </em>not a suitable choice for acute myocardial infarction on an immediate basis.</p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em>Thrombolytics such as the recombinant tissue plasminogen activator (tPA) reduce morbidity and mortality if used shortly after an acute myocardial infarction (AMI).</em></li>\r\n</ul>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Streptokinase is contraindicated in old patients</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Streptokinase induced hypotension</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Alteplase does not cross react with anti-streptococcal antibodies</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Alteplase has no risk of bleeding</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 64-year-old female patient came to the medicine department seeking treatment for myocardial infarction with a recent history of streptococcal infection. Her physician decided to give her Alteplase to dissolve the coronary artery clot. Which of the following reasons is true regarding choosing Alteplase over Streptokinase in this patient? </span></p>",
      "unique_key": "DT1293239",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293239,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412239e51025d-69be-49ee-bec1-2578fa6.jpg\">\r\n<p><strong><u>Streptokinase </u></strong></p>\r\n<ul>\r\n<li><em>Obtained from <u>&beta; haemolytic Streptococci</u> group C</em><em>. It is the first fibrinolytic drug to be used clinically, but is <strong><u>not employed now because it is non-fibrin specific, i.e. activates both circulating as well as fibrin bound plasminogen. </u></strong>Therefore, it depletes circulating fibrinogen and predisposes to bleeding.</em></li>\r\n<li><em>Compared to newer, more fibrin-specific tissue plasminogen activators (alteplase, etc.) it is <u>less effective in opening occluded coronary arteries, and causes a less reduction in MI related mortality</u>.</em></li>\r\n<li><em>Other disadvantages are </em><em>needed for a <u>loading dose due to presence of anti-streptococcal antibodies. </u><strong>Streptokinase is antigenic-can cause hypersensitivity reactions; anaphylaxis occurs in 1-2% patients</strong>.</em></li>\r\n<li><em>Fever, hypotension and arrhythmias are reported.</em><em> It <strong>cannot be used a second time due to neutralization by antibodies generated in response to the earlier dose</strong>.</em></li>\r\n</ul>\r\n<p><strong><u>Alteplase </u></strong></p>\r\n<ul>\r\n<li><strong><em><u>Recombinant tissue plasminogen activator</u></em></strong><em> (rt-PA) It catalyses the cleavage of endogenous plasminogen to generate plasmin, and is <u>moderately specific for fibrin bound plasminogen, so that circulating fibrinogen is lowered only by ~ 50%.</u></em></li>\r\n<li><em>It is rapidly cleared </em><em>by the liver and is inactivated by plasminogen Activator inhibitor-1 (PAI-1). The plasma t&frac12; is 4-8 min. <u>Because of the short t&frac12;, it needs to be given by slow i.v. infusion and often requires heparin coadministration</u>.</em></li>\r\n<li><em>Aspirin is also routinely given after establishing reperfusion. Risk of bleeding (0.5-5%) is the most important concern.</em></li>\r\n<li><strong><em>Alteplase is nonantigenic, but nausea, mild hypotension and fever may occur. It is expensive.</em></strong></li>\r\n</ul>\r\n<p>Option A: All Thrombolytics are relatively contraindicated In patient above &gt;75 years.</p>\r\n<p>Option B: Streptokinase and alteplase both cause hypotension. However, alteplase is preferred due to clot selectivity.</p>\r\n<p>Option D: With Alteplase, <em>risk of bleeding (0.5-5%) is the most important concern. </em></p>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li><em>Streptokinase is <strong>antigenic-can cause hypersensitivity reaction.</strong> It cannot be used second time due to <strong>neutralization by antibodies generated in response to the earlier dose.</strong></em></li>\r\n</ul>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitroglycerin</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Alteplase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old woman admitted to the coronary unit because of a myocardial infarction received an appropriate multidrug therapy. The next day she complained of an abrupt headache, followed shortly by vomiting and loss of consciousness. A computed tomography scan of the brain confirmed the diagnosis of stroke due to cerebral hemorrhage. Which of the following drugs most likely contributed to the appearance of the patient's stroke?</span></p>",
      "unique_key": "DT1293241",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293241,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>The standard therapy of myocardial infarction (MI) includes an intravenous thrombolytic drug (alteplase, reteplase, etc.), which is most effective in the first few hours after onset.</p>\r\n<p>Bleeding (most common in cerebral vessels) is the most frequent adverse effect of these drugs.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241223e3735c0b-5531-4029-9ea3-e58ad46.jpg\">\r\n<p><strong>Option A</strong>: Aspirin, if not contraindicated, is given at presentation and daily indefinitely thereafter. Its antiplatelet effect reduces short- and long-term mortality. <strong>Bleeding, however, is not as common as with thrombolytic drugs.</strong></p>\r\n<p><strong>Option B:</strong> Beta-blockers, if not contraindicated, are given within the first few hours after onset because they reduce recurrence rate and mortality. <strong>Bleeding is not an adverse effect of this drug class.</strong></p>\r\n<p><strong>Option C:</strong> Nitroglycerin is recommended for the first 24 to 48 hours in patients with MI and heart failure or hypertension. <strong>Bleeding is not an adverse effect of this drug class.</strong></p>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li><strong><em>Bleeding (most common in cerebral vessels) is the most frequent adverse effect </em></strong><em>of these drugs, which is because of the dissolution of an already formed clot.</em></li>\r\n</ul>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Protamine</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">LMWH</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Coumarin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 63-year-old man has a history of atrial fibrillation. To reduce his risk of a stroke, his physician had given him an anticoagulant medication. This agent comes with risks of spontaneous hemorrhage. To monitor the appropriatenessof the current dosage of the medication, the patient comes in frequently to have the laboratory check his prothrombin level. Which of the following medication most likely this patient is taking?</span></p>",
      "unique_key": "DT1293242",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293242,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em>Coumarin is commonly used in patients <strong>with atrial fibrillation </strong>for prevention of thromboembolic events, such as stroke. </em></p>\r\n<p><strong><em>Prothrombin time(PT)</em></strong><em> should be frequently monitored in patients taking coumarin, as bleeding is a common adverse effect. </em></p>\r\n<p><strong>Dose regulation </strong></p>\r\n<ul>\r\n<li>The <em>dose of vit K antagonist oral anticoagulant must be individualised by <strong>repeated measurement of prothrombin time;</strong> the aim is to achieve a therapeutic effect without unduly increasing the chances of bleeding.</em></li>\r\n</ul>\r\n<p><strong><em><u>Recommended INR for various indications of oral anticoagulants</u></em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412230a56cac8-69cb-48f4-b421-0f3746a.jpg\">\r\n<p><strong><em><u>Comparative differences between Warfarin and Heparin</u></em></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024122364a97318-4da6-419e-84b4-af9a07c.jpg\">\r\n<p><strong>Option A</strong>: Heparin is monitored with <strong>partial thromboplastin time(aPTT). </strong></p>\r\n<p><strong>Option B</strong>: <strong>Protamine is an agent used for heparin reversal.</strong></p>\r\n<p><strong>Option C</strong>: <strong>LMWH usually requires no monitoring</strong></p>\r\n<p><strong><u>Key Takeaway :</u></strong></p>\r\n<ul>\r\n<li><em>Warfarin is commonly used in patients with <strong>atrial fibrillation </strong>for prevention of thromboembolic events &amp; <strong>Prothrombin time(PT)</strong> should be frequently monitored in patients taking the same</em></li>\r\n</ul>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin </span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Rivaroxaban</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin </span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Dabigatran</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 75-year-old male patient post surgery was admitted to the emergency department with deep vein thrombosis. He was later started on an Anticoagulant therapy by his attending physician. Next day, the patient presented with the features shown in the diagram below. Which of the following drug is most likely implicated for this adverse effect?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412235af6898a-701e-4fb8-9de5-770ac7f.jpg\"></span></p>",
      "unique_key": "DT1293244",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293244,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412235096c23f-fc07-4ce1-ae83-e8cb240.jpg\"><p><strong>Option A, B &amp; D: </strong><em>The major adverse effect of these drugs also is bleeding, but all of them don&rsquo;t lead to <strong>ecchymosis</strong></em> <em>as is the case here. </em></p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em><u>Bleeding is the most common adverse effect of all anticoagulants</u></em>. If a patient develops bleeding due to overdose of warfarin, <strong>four factor concentrate or fresh frozen plasma</strong> (to supply clotting factors) is the treatment of choice but <strong><em>specific antidote is vitamin K</em></strong><strong><em>1</em></strong> (but the action will be delayed).</li>\r\n</ul>",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">A</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">B</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">C</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 77-year-old male, Sureshbhai presented to medicine OPD with fever, malaise, sore throat with mouth ulcers. He had a history of myocardial infarction, for that he was on antiplatelet drugs. His complete blood count shows: Hb 13 g/dL, Platelet count 100000/mm3, WBC 1000/mm3. If the above given antiplatelet drug is suspected to be responsible for the above symptoms of the patients, which of the following is most likely the mechanism of by <br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20241223255cb279-28b4-40b9-9ea6-b1b6ecc.jpg\"><br>Which this antiplatelet agent is acting? </span></p>",
      "unique_key": "DT1293247",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293247,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>Ticlopidine produces serious adverse effects like neutropenia, thrombocytopenia, haemolysis, jaundice. </u></em>Which is P2Y12 Inhibitors, so answer is C.</p>\r\n<p><strong>Ticlopidine</strong></p>\r\n<ul>\r\n<li>It is the first thienopyridine drug that acts by blocking the P2Y12 type of purinergic receptors on the surface of platelets and inhibits ADP-induced aggregation.</li>\r\n</ul>\r\n<p><strong><u>Ticlopidine produces beneficial effects in following conditions </u></strong></p>\r\n<ul>\r\n<li><em><u>TIAs stroke prevention, </u></em></li>\r\n<li><em><u>UA,</u></em></li>\r\n<li><em><u>Secondary prophylaxis of MI</u></em></li>\r\n<li><em><u>Synergized with aspirin to lower the incidence of restenosis after PCI and stent thrombosis. </u></em></li>\r\n</ul>\r\n<p><strong>However, it produced serious adverse effects like </strong></p>\r\n<ul>\r\n<li><em>Neutropenia, </em></li>\r\n<li><em>Thrombocytopenia</em></li>\r\n<li><em>Haemolysis</em></li>\r\n<li><em>Jaundice.</em></li>\r\n</ul>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li><em>Ticlopidine produces serious adverse effects like <strong>neutropenia, thrombocytopenia, haemolysis, jaundice.</strong></em></li>\r\n</ul>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Clopidogrel </span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Dipyridamole</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Abciximab</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old male patient presented to the emergency department of a hospital with acute left-sided chest pain. ECG of the patient confirms it to be non ST elevation myocardial infarction. Which of the following drug is useful in this patient acts by inhibiting platelet aggregation via blocking Purinergic receptors?</span></p>",
      "unique_key": "DT1293248",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293248,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202412236dcb78c0-64d6-4050-ae4b-63b92e8.jpg\">\r\n<p><strong>Clopidogrel:</strong></p>\r\n<ul>\r\n<li><em>This is a more potent congener of </em><em>ticlopidine that acts by <u>irreversibly blocking the P2Y12 type of purinergic receptor on the surface of platelets</u>.</em></li>\r\n<li><em>This Gi-coupled GPCR <strong>mediates ADP-induced platelet aggregation by inhibiting adenylyl cyclase and decreasing cAMP</strong>.</em></li>\r\n<li><em>Clopidogrel is also a </em><em> It is a slow acting drug; <strong>antiplatelet action takes about 4 hours to start and develops over days.</strong></em></li>\r\n<li><em>Since </em><strong><em>CYP2C19 exhibits genetic polymorphism, the activation of clopidogrel and consequently its antiplatelet action shows high interindividual variability.</em></strong></li>\r\n<li><em>Combination of clopidogrel and aspirin is synergistic in preventing ischaemic episodes. This <strong>&lsquo;dual antiplatelet therapy&rsquo; (DAPT) is also utilized for checking</strong></em><strong><em> the restenosis of stent</em></strong></li>\r\n<li><strong><em>The most important adverse effect is bleeding. </em></strong><em>Neutropenia is rare with clopidogrel. Other side effects are diarrhoea, epigastric pain and rashes.</em></li>\r\n</ul>\r\n<p><strong>Option B: </strong><em>Dipyridamole acts by <strong>inhibiting phosphodiesterase </strong>(which breaks down cAMP) resulting in increased cAMP that potentiates prostacyclins and thus anti-aggregation.</em></p>\r\n<p><strong>Option C: </strong><em>Abciximab is a monoclonal antibody <strong>against Gp IIb/IIIa receptor. </strong>Gp IIb/IIIa antagonists are strongest antiplatelet drugs as they block aggregation induced by all agonists.</em></p>\r\n<p><strong>Option D: </strong><em>Warfarin is an oral anticoagulant and acts by inhibiting the activation of <strong>vitamin K dependent clotting factors.</strong></em></p>\r\n<p><strong><u>Key Takeaway: </u></strong></p>\r\n<ul>\r\n<li><em>Clopidogrel is a congener of ticlopidine that acts by <u>irreversibly blocking the P2Y12 type of purinergic receptor on the surface of platelets.</u></em></li>\r\n</ul>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Clopidogrel</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Prasugrel</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Ticagrelor</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Ticlopidine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old male patient with a recent history of acute myocardial infarction was prescribed an antiplatelet agent acting via P2Y12 inhibition. Later that patient came to the medicine department with complaints of Dyspnea. Which of the following agents is commonly associated Dyspnea?</span></p>",
      "unique_key": "DT1293249",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293249,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em>Ticagrelor is more commonly associated with dyspnea. </em></strong></p>\r\n<p>The dyspnea is <strong><u>transient and not associated with pulmonary disease</u></strong>. Other Side effects are dizziness, nausea, <u>shortness of breath, tightness in chest</u> and irregular pulse.</p>\r\n<p><strong><em>Dyspnea </em></strong>is more commonly seen with <strong>reversible</strong> P2Y12 inhibitors like ticagrelor, cangrelor and elinogrel. It is <strong>uncommon with irreversible P2Y12 </strong><strong>inhibitors like clopidogrel, prasugrel and ticlopidine.</strong></p>\r\n<p><strong>Option A, B &amp; D</strong>: Dyspnea is <strong><u>uncommon with irreversible P2Y12 inhibitors like clopidogrel, prasugrel and ticlopidine.</u></strong></p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em>Ticagrelor is more commonly associated with dyspnea amongst P2Y12 inhibitors. <strong>Dyspnea is more seen with reversible P2Y12 inhibitors.</strong></em></li>\r\n</ul>",
      "correct_choice_id": 173,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Streptokinase</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Clopidogrel</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Abciximab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old woman has a temporary loss of peripheral vision and dizziness that lasts for approximately 10 minutes. Her family history reveals that her mother also had Thromboembolic disease. Which of the following would be the best outpatient prophylactic regimen for this patient 2 days after these symptoms appeared?</span></p>",
      "unique_key": "DT1293251",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293251,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em><u>The patient has symptoms consistent with a transient ischemic attack (TIA). Prophylactic antiplatelet therapy should be instituted while the diagnosis is confirmed.</u></em></p>\r\n<p><strong><em><u>Cerebrovascular disease </u></em></strong></p>\r\n<ul>\r\n<li><em>Antiplatelet drugs do not alter the course of stroke due to cerebral thrombosis.</em></li>\r\n<li><em>However, <u>aspirin has reduced the incidence of TIAs and of stroke in patients with TIAs.</u></em></li>\r\n<li><em>Occurrence of stroke is also reduced in patients with persistent atrial</em><em> fibrillation and in those with a history of stroke in the past.</em></li>\r\n<li><strong><em><u>Aspirin or clopidogrel is given to all patients of TIAs who are not to be</u></em></strong><strong><em><u> treated with anticoagulants</u></em></strong><em>.</em></li>\r\n<li><em>Though short-term use of aspirin + clopidogrel DAPT may be beneficial, long-term use of the <strong><u>combination increases the risk of haemorrhage</u>.</strong></em></li>\r\n</ul>\r\n<p><strong>Option A</strong>: Streptokinase is thrombolytic that may be used within hours of a thrombotic stroke <strong>but not after 2 days after a possible TIA.</strong></p>\r\n<p><strong>Option C</strong>: Heparin is <strong>not suitable for outpatient use. </strong></p>\r\n<p><strong>Option D : </strong><em>Abciximab <strong>does not alter the course of stroke due to cerebral thrombosis.</strong></em><strong> It's not suitable also for outpatient use dt Intravenous Route of administration.</strong></p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><em>Clopidogrel is given to all patients of <strong>TIAs who are not to be treated with anticoagulants.</strong></em></li>\r\n</ul>",
      "correct_choice_id": 182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Clopidogrel</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Abciximab</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Recombinant factor VIIa</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old man admitted to the hospital with a myocardial infarction underwent a percutaneous coronary angioplasty for the revascularization of his left coronary. Which of the following drugs was most likely given intravenously during the procedure?</span></p>",
      "unique_key": "DT1293253",
      "question_audio": null,
      "question_video": null,
      "map_id": 1293253,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><em>Various anticoagulation regimens are always <u>performed before, during, and after angioplasty to reduce the incidence of thrombosis</u>. </em></p>\r\n<p><strong><em><u>Heparin and abciximab are the two drugs given intravenously for this purpose.</u></em></strong></p>\r\n<p><strong><em><u>Acute coronary syndromes (ACSs)</u></em></strong></p>\r\n<ul>\r\n<li><strong><u>Soluble aspirin (325 mg oral) and a LMW heparin (s.c.) are given at presentation to all patients with ACS.</u></strong></li>\r\n</ul>\r\n<p><strong><em>Unstable angina (UA) :</em></strong></p>\r\n<ul>\r\n<li><em>Aspirin reduces the risk of progression to MI and sudden death.<u>Clopidogrel is generally combined with</u> <u>aspirin,</u> or may be used </em><em>as an alternative if aspirin cannot be given.</em></li>\r\n<li><em>For maximum protection, the <u>antiplatelet drugs are supplemented with LMW heparin followed by warfarin.</u></em></li>\r\n</ul>\r\n<p><strong><em>NSTEMI : </em></strong></p>\r\n<ul>\r\n<li><em>Patients of NSTEMI who are managed without PCI/thrombolysis are generally put on a <u>combination of aspirin + clopidogrel or ticagrelor, which is continued for upto one year.</u></em></li>\r\n</ul>\r\n<p><strong><em>STEMI : </em></strong></p>\r\n<ul>\r\n<li><em><u>Primary PCI with or without stent placement is the procedure of choice for all STEMI as well as high risk NSTEMI patients who present within 12 hours.</u></em></li>\r\n<li><em><u>Prasugrel or ticagrelor + aspirin is the antiplatelet regimen</u></em><em> most commonly selected for patients who are to undergo PCI.</em></li>\r\n<li><strong><em>The GPIIb/IIIa antagonists are the most powerful antiplatelet drugs. </em></strong><em><u>Abciximab/eptifibatide/tirofiban infused i.v. along with oral aspirin and s.c. heparin markedly reduce incidence of restenosis and subsequent MI after coronary angioplasty.</u></em></li>\r\n<li><em>The GPIIb/IIIa antagonists are infused for a maximum of 72 hours.</em></li>\r\n</ul>\r\n<p><strong>Option A &amp; B</strong>: <em>Warfarin and clopidogrel both are given <strong>orally</strong>.</em></p>\r\n<p><strong>Option D</strong>: <em>Recombinant factor VIIa is given intravenously for treatment of <strong>haemophilia patients. </strong></em></p>\r\n<p><strong><u>Key Takeaway : </u></strong></p>\r\n<ul>\r\n<li><strong><u>Heparin and abciximab</u></strong> <em>are the two drugs given <strong>intravenously</strong> for </em>percutaneous coronary angioplasty procedure.</li>\r\n</ul>",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}